+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07555483

Comparing Weekly Subcutaneous and Intravenous Alpha1-Proteinase Inhibitor Doses for Adults with Alpha1-Antitrypsin Deficiency

Led by Grifols Therapeutics LLC · Updated on 2026-10-26

40

Participants Needed

22

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two different weekly doses of Alpha1-Proteinase Inhibitor Alpha1-PI given by injection under the skin compared with the standard intravenous doses in adults with Alpha-1 Antitrypsin Deficiency. This Phase 3, open-label study aims to understand how the body processes the medicine and to assess the safety and tolerability of the different doses. Participants are randomly assigned to treatment groups in a parallel design, with both doctors and participants aware of the assigned treatment. Participants undergo two treatment periods the first with intravenous IV Liquid Alpha1-PI given weekly at either 60 mgkg or 120 mgkg for 8 weeks, followed by a second period with subcutaneous SC Alpha1-PI 15% injection at corresponding higher doses 90 mgkg or 180 mgkg also given weekly for 8 weeks. Participants receive each dosing schedule sequentially to compare pharmacokinetics and safety between IV and SC administration. During the study, participants have regular visits to monitor steady-state levels of Alpha1-PI in the blood, lung function tests, and safety assessments. Key measurements include the area under the curve AUC of Alpha1-PI over each weekly interval and trough serum levels at specific weeks. The study includes screening, 16 weeks of treatment divided into two 8-week periods, and ongoing safety and tolerability evaluations throughout.

CONDITIONS

Brief Title

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

Research Team

B

Beatriz Garcia Castro

L

Lydia Martinez Garrido

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here